Mander A J, Loudon J B
University Department of Psychiatry, Royal Edinburgh Hospital.
Lancet. 1988 Jul 2;2(8601):15-7. doi: 10.1016/s0140-6736(88)92947-9.
Fourteen patients with a history of mania satisfying DSM-III criteria were entered into a randomised double-blind placebo-controlled crossover trial, spending four weeks on each of lithium and placebo. All patients had been well and stable on lithium for at least 18 months and were not taking any other psychotropic drugs. Seven patients (50%) had a relapse of their manic illness and a further two had to be withdrawn because they recognised signs of incipient relapse. One of these became overtly manic after restarting lithium. The seven definite and the two possible relapses occurred in the placebo phase; this finding was unlikely to have arisen by chance. The relapses started 13-19 days after placebo substitution. These results have important implications in the management of lithium prophylaxis by all doctors, particularly those who, for any reason, are considering withdrawal of lithium from their patients.
14名符合《精神疾病诊断与统计手册》第三版标准的躁狂症患者进入了一项随机双盲安慰剂对照交叉试验,分别服用锂盐和安慰剂各4周。所有患者此前服用锂盐状态良好且稳定至少18个月,并且未服用任何其他精神药物。7名患者(50%)躁狂症复发,另有2名患者因察觉到复发迹象而不得不退出试验。其中1名患者在重新服用锂盐后出现明显躁狂症状。7例确诊复发和2例可能复发均发生在安慰剂阶段;这一结果不太可能是偶然出现的。复发在换用安慰剂后13 - 19天开始。这些结果对所有医生在锂盐预防性治疗的管理方面具有重要意义,尤其是那些出于任何原因考虑让患者停用锂盐的医生。